SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced that the company has entered into a license, development and commercialization agreem...
Third asset to advance into clinical trials, validating broad potential of Launch-iT platform All subjects treated with first dose of AVX70371 Launch-...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJC...
Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, toda...
As the world recalibrates its life sciences infrastructure post-pandemic, Australia is stepping up as a regional powerhouse in biomanufacturing—espec...
BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by t...
CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that d...
Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infectio...
Enter Generative AI: A Paradigm Shift Today, generative AI is changing this equation. Unlike traditional AI that analyzes existing data, generative AI can...
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...
© 2025 Biopharma Boardroom. All Rights Reserved.
